He describes how Rigel became focused on both IRAK 1 and 4, a novel mechanism in the area of hematology, and what is next for the company after the ASH presentation. Coverage brought to you by

Shares an update on the company's ASH data, and also on plans to move into earlier lines of treatment. A registrational study is already set to begin in early 2026. Coverage brought to you by

He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin. Coverage brought to you by

Co-Founder and CEO Nate Fernhoff walks us through this platform and the clinical data that Orca has previously announced, and new data at ASH. Plus, a journey through the patient experience of how this works. Coverage brought to you by

She highlights anito-cel's new efficacy data, and a safety profile that continues to look clean. Plus, she thinks a CD19 + CD20 dual antigen CAR-T could be best in class in the future, and why Kite acquired an in vivo CAR-T company in August for $350M. Coverage brought to you by

Founder and CEO Adam Rosenthal describes the unmet need for patients with this condition, and walks us through VGA039, a protein S modulator. Coverage brought to you by

He says he is confident in the commercial leadership profile that Carvykti has established, and walks us through potential follow-on pipeline programs. Coverage brought to you by

Founder and CEO Bent Jakobsen describes the science behind the platform, which he believes is unique in that it is delivered systemically, but is designed to bypass healthy tissue and only target tumor cells (without the need for screening). It targets the integrin αvβ6.

Sean Bohen explains what he believes is the significance of the Roche announcement, and why he believes Olema's could potentially be a best in class oral SERD. Plus, a preview of data that will deliver sometime next year. Coverage brought to you by

He discusses Zealand's partnership with Roche, and new data that will be coming next year. Plus, the company's partnership with Boehringer on survodutide. Coverage brought to you by

CEO Laurent Levy introduces us to the company's Curadigm Nanoprimer platform and explains its potential use cases. Plus, an update on the company's JNJ partnership, and a recent royalty deal. Coverage brought to you by

He mentions momelotinib, Blenrep, B7-H3, depemokimab, efimosfermin, IL-33, TSLP, and more. Plus, GSK's dealmaking strategy. Coverage brought to you by

CEO Kenneth Galbraith explains the new dual business focus and walks us through the topline HER2 data. Coverage brought to you by

He covers the company's oral IL-23 (partnered with JNJ), rusfertide (partnered with Takeda), and a new early stage obesity program. Coverage brought to you by

He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.

CEO Michael Henderson walks us through what will be a busy year for the company. Coverage brought to you by

CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS. Coverage brought to you by

CEO Mike Cloonan describes the unmet need for better treatments that exists today in CF, and discusses Sionna's development plans. Coverage brought to you by

He discusses the pathway and gedatolisib's ability to cover it holistically. Plus, future plans for filing and additional data in breast cancer and beyond. Coverage brought to you by

CEO Cameron Turtle describes the improvements Spyre is making in its therapies. 2026 is going to be a data rich year for IBD. Coverage brought to you by